Other meanings of Mitochondrial replacement therapy
Genetic medicine
Mitochondrial replacement therapy is a medical technique replacing faulty mitochondria to prevent inherited mitochondrial disease. It combines nuclear genetic material from intended parents with healthy mitochondria from a donor, usually through in vitro fertilization, so that an embryo inherits the parents’ nuclear DNA but little or no disease-causing mitochondrial DNA.
Mitochondrial replacement therapy prevents transmission of disease-causing mitochondrial DNA by replacing the mother’s mitochondria during assisted reproduction. Mitochondria generate cellular energy and contain a small, separately inherited genome; pathogenic variants can cause progressive disorders affecting the brain, muscles, heart, eyes, or other organs. Because mitochondria are usually transmitted through the egg, a woman carrying a harmful mitochondrial variant may pass it to all or some of her children. The proportion of abnormal mitochondria, called heteroplasmy, helps influence whether disease appears and how severe it becomes.
The treatment preserves the intended parents’ nuclear DNA while supplying healthy mitochondria from an oocyte donor. In the principal approaches, the nuclear material is moved either before fertilization, as in maternal-spindle transfer, or after fertilization, as in pronuclear transfer. The reconstructed embryo is then cultured and transferred like an IVF embryo.
Mitochondrial replacement therapy remains a specialized reproductive intervention rather than a routine treatment. A 2016 report described a live birth after spindle transfer for a woman at risk of transmitting Leigh syndrome, providing an early clinical demonstration but not evidence that every mitochondrial disorder can be prevented. Subsequent clinical programs have emphasized careful genetic testing, embryo selection, and long-term follow-up.
The United Kingdom became the first country to create a regulated pathway for mitochondrial donation, following parliamentary approval of regulations in 2015.1 The Human Fertilisation and Embryology Authority assesses licensed applications individually, and clinics must meet requirements for patient selection, laboratory practice, consent, and monitoring. Laws and policies differ elsewhere, so availability depends on national regulation rather than scientific feasibility alone.
The main benefit is reducing the probability that a child will inherit a serious mitochondrial disorder, particularly when no unaffected biological-child option is acceptable to the family. The technique does not repair the parents’ nuclear genes, and it cannot treat an existing child or reverse disease in an already formed organism. Residual abnormal mitochondrial DNA can remain after laboratory manipulation, creating uncertainty about the eventual level of heteroplasmy.
Research has also examined mitochondrial–nuclear compatibility, embryo development, and the possibility that a small amount of carried-over mutant mitochondrial DNA could expand in later development. Long-term evidence is necessarily limited because the children born after these procedures are still young. Ethical debate concerns the future child’s consent, donor anonymity and identity, the status of mitochondrial DNA as heritable material, and whether the intervention should be regarded as a form of germline modification. The Nuffield Council on Bioethics has treated welfare, transparency, and responsible governance as central safeguards.2
Several technical details make mitochondrial replacement more complicated than a simple transfer of “healthy cells.” Donor mitochondria contribute mitochondrial DNA but not the nuclear traits traditionally associated with appearance, personality, or most inherited characteristics. The donor’s mitochondrial genome is nevertheless biologically transmitted through the embryo, which is why public descriptions sometimes use the phrase “three-person IVF,” although that label can obscure the very small genetic contribution involved.
Different mitochondrial disorders behave differently: some arise from mitochondrial DNA variants, while others result from nuclear genes that control mitochondrial function and therefore are not prevented by mitochondrial donation. Preimplantation genetic testing may sometimes identify embryos with low mutant loads without using a donor. Researchers have also studied mitochondrial donation as a way to avoid repeated transmission across generations, but clinical decisions require disease-specific genetic counseling, because heteroplasmy thresholds and reproductive options vary substantially between families.
Mitochondrial replacement therapy is distinct from experimental mitochondrial gene-editing methods and from treatments intended to improve mitochondrial function in people who already have mitochondrial disease.
Help improve the encyclopedia. Reports go straight to the site manager.